A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
Status:
Completed
Trial end date:
2005-05-28
Target enrollment:
Participant gender:
Summary
This study was a double-blind, placebo-controlled, cross-over, single-center study of
desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal
allergic rhinoconjunctivitis. This study was performed to examine the effects of
desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis
induced by direct conjunctival challenges with a previously identified sensitizing antigen,
in the eyes of a subject known to be sensitive to the antigen.